Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | FABP4 | P15090 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5367871 | 0.83 | MCL1 (0.55) | MCL1TSHRALDH1A1HPGD | |
| SCHEMBL14958764 | 0.81 | TSHR (0.44) | MCL1TSHRALDH1A1MAPTHPGD | |
| SCHEMBL3440052 | 0.78 | MCL1 (0.39) | MCL1TSHRFFAR1ALDH1A1HPGD | |
| SCHEMBL11504186 | 0.78 | MCL1 (0.58) | MCL1TSHRFFAR4FFAR1ALDH1A1 | |
| SCHEMBL15412587 | 0.76 | OGG1 (0.43) | MCL1TSHRALDH1A1HPGDL3MBTL1 | |
| SCHEMBL2280556 | 0.75 | TSHR (0.57) | MCL1TSHRFFAR4FFAR1PPARG | |
| SCHEMBL3177267 | 0.74 | TSHR (0.61) | MCL1TSHRFFAR4FFAR1PPARG | |
| SCHEMBL7827991 | 0.74 | MCL1 (0.69) | MCL1FFAR4FFAR1ALDH1A1 | |
| SCHEMBL14356223 | 0.74 | PTGS2 (0.46) | ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL16607503 | 0.73 | PPARA (0.50) | FFAR4FFAR1PPARAALDH1A1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250009915-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM CORPORATION (JP) | 2025-01-09 | — | — | US | disclosed |
| EP-4249471-A2 | PHARMACEUTICAL COMPOSITION OF A NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM Corporation (JP) | 2023-09-27 | — | — | EP | disclosed |
| EP-3929196-B1 | PHARMACEUTICAL COMPOSITION OF A NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM CORP (JP) | 2023-08-23 | — | — | EP | disclosed |
| US-20230136073-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM CORPORATION (JP) | 2023-05-04 | — | — | US | disclosed |
| CN-111171026-B | Production intermediate for nitrogen-containing compound or salt thereof | 富士胶片株式会社 | 2023-03-03 | — | — | CN | disclosed |
| US-11426473-B2 | Nitrogen-containing compound or salt thereof, or metal complex thereof | FUJIFILM CORPORATION (JP) | 2022-08-30 | — | — | US | disclosed |
| EP-3929196-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM Corporation (JP) | 2021-12-29 | — | — | EP | disclosed |
| EP-3050878-B1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM CORP (JP) | 2021-10-27 | — | — | EP | disclosed |
| EP-3275883-B1 | METHOD FOR PRODUCING NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, AND PRODUCTION INTERMEDIATE OF SAME | FUJIFILM CORP (JP) | 2021-06-02 | — | — | EP | disclosed |
| US-20210015802-A1 | METHOD FOR MANUFACTURING NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF AND MANUFACTURING INTERMEDIATE OF NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2021-01-21 | — | — | US | disclosed |
| US-20020061909-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MI REAL ESTATE, LLC | 2002-05-23 | — | — | US | disclosed |
| US-20020041878-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2002-04-11 | — | — | US | disclosed |
| US-20020015680-A1 | QUINOLONE VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | CITIZENS BANK, N.A. | 2002-02-07 | — | — | US | disclosed |
| WO-2002004030-A2 | STABLE RADIOPHARMACEUTICAL COMPOSITIONS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001097848-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
| US-6322770-B1 | FOR DIAGNOSIS AND TREATMENT OF CANCER, IMAGING TUMORS, MONITORING THERAPEUTIC ANGIOGENESIS TREATMENT AND DESTRUCTION OF NEW ANGIOGENIC VASCULATURE; COMPRISED OF TARGETING MOIETY THAT BINDS TO RECEPTOR AND RADIOISOTOPE | DUPONT PHARMACEUTICALS COMPANY | 2001-11-27 | — | — | US | disclosed |
| EP-1140204-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140203-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035488-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000035492-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136073-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | SLC39A3, SLC39A14, SLC39A11 | MCL1 2304/4885TSHR 1920/4885FFAR4 4195/4885 |
| US-20210015802-A1 | METHOD FOR MANUFACTURING NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF AND MANUFACTURING INTERMEDIATE OF NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF | C5, C9, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MCL1 3250/4885TSHR 3329/4885FFAR4 4630/4885 |
| US-20020015680-A1 | QUINOLONE VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | ADGRF1, QRFPR, ADGRE5 | MCL1 1210/4885TSHR 899/4885FFAR4 460/4885 |
| US-20020041878-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | MCL1 691/4885TSHR 428/4885FFAR4 409/4885 |
| US-20020061909-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | MCL1 649/4885TSHR 410/4885FFAR4 392/4885 |
| US-11426473-B2 | Nitrogen-containing compound or salt thereof, or metal complex thereof | SLC39A3, SLC39A14, SLC39A11 | MCL1 2332/4885TSHR 2000/4885FFAR4 4087/4885 |
| US-20250009915-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | SLC39A3, SLC39A14, SLC39A11 | MCL1 2311/4885TSHR 1922/4885FFAR4 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.